The Supreme Court's examination of mandatory Nucleic Acid Testing (NAT) in blood banks raises fundamental questions about the State's obligation under Article 21. Discuss the public health, legal, and fiscal dimensions of making NAT compulsory across India.

Q. The Supreme Court's examination of mandatory Nucleic Acid Testing (NAT) in blood banks raises fundamental questions about the State's obligation under Article 21. Discuss the public health, legal, and fiscal dimensions of making NAT compulsory across India. (15 marks, 250-350 words)

Human blood is a "drug" under the Drugs and Cosmetics Act, 1940, and NAT detects viral genetic material directly, closing the serological window period that antibody-based ELISA misses. The Supreme Court's examination of a plea for mandatory NAT [1] therefore tests whether safe blood is an enforceable facet of Article 21.

Public health dimension - ELISA detects antibodies/antigens; donations in the window period pass undetected. NAT detects HIV/HCV RNA and HBV DNA, reducing residual transfusion risk to roughly one in a million [4]. - A 15-year Indian retrospective study found NAT intercepted 205 infected units missed by serology, with HBV forming ~80% of the additional yield [4]. - Repeat-transfusion patients — thalassaemia, haemophilia, dialysis and oncology cases — face cumulative exposure; WHO requires quality-assured screening of every donation, a standard weakest in lower-income settings [2].

Legal–constitutional dimension - Article 21 jurisprudence (Paschim Banga Khet Mazdoor Samity, 1996) obliges the State to provide adequate medical care; the petitioner extends this to transfusion safety [1]. - The Centre's competence runs through Schedule F, Part XII-B of the Drugs and Cosmetics Rules and CDSCO standards, while public health remains Entry 6, State List — a mandate needs rule amendment and a revised National Blood Policy [5], not judicial fiat alone. - The Bench's caution reflects judicial restraint in technical standard-setting [1].

Fiscal–administrative dimension - Individual-donation NAT is capital-intensive; the Court itself flagged the burden on fiscally stressed States [1]. - Pooled NAT and centralized testing — as in Madhya Pradesh's model [6] — plus the Ministry's hub-and-spoke blood services architecture deliver economies of scale [3]. - An unfunded mandate would widen inter-State inequity; phased central co-financing through NBTC/NACO is more workable [3].

Blood safety is thus a constitutional promise mediated by capacity. A calibrated path — regional NAT hubs, pooled testing and central assistance, sequenced from high-burden districts — reconciles Article 21 with cooperative federalism, advancing SDG-3's universal health coverage goal.

(~315 words)

Sources: 1. The Hindu, "SC to look into feasibility of NAT for blood transfusion" (3 March 2026) — pendency of the plea, Article 21 argument, Bench's cost-effectiveness concern 2. WHO, Blood safety and availability (fact sheet) — mandatory screening of all donations; quality-assurance gaps in lower-income countries 3. PIB/MoHFW, National Video Conference on Blood Transfusion Services (NACO) — hub-and-spoke architecture, phased TTI screening upgrades, district coverage goal 4. "Added Value of Nucleic Acid Testing in Blood Banks: A 15-Year Retrospective Study from India", NIH/PMC — 205 additional TTI detections, HBV-dominant yield, residual risk ~1 in a million 5. PIB, National Blood Policy — national policy framework for blood safety 6. "Blood Safety: The Madhya Pradesh Centralized NAT Model for Blood Donor Screening", NIH/PMC — centralized/pooled NAT model and its economies of scale